The purpose of this study is to determine if there is a role of prophylactic therapy with tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse. 150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2 groups. Group 1 -of 75 persons will recieve tamsulosin 0.4 mg x 1/d 2 days before the lithotripsy . Group 2 - of 75 persons will...
Date First Received: June 19, 2007
Last Updated: June 20, 2007
Verified by: HaEmek Medical Center, Israel, June 2007
Clinical Trial Phase: N/A | Start Date: May 2007
Overall Status: Recruiting
Brief Summary
Condition Keyword(s):
Intervention(s):
The purpose of this study is to determine if there is a role of prophylactic therapy with tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse.
150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2 groups.
Group 1 -of 75 persons will recieve tamsulosin 0.4 mg x 1/d 2 days before the lithotripsy .
Group 2 - of 75 persons will not recieve tamsulosin. 48 hour after the ESWL all 2 group will take abdominal radiograph to evaluate the presence of steinstrasse.
Study Type: Observational
Study Design: Screening, Longitudinal, Defined Population, Prospective Study
Intervention(s) in this Clinical Trial
- Drug: tamsulosin 0.4mg
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- size of stone 1-2 cm
Exclusion Criteria:
- ureteral stricture Presence of internal stent prior use of alfa bloker prior ESWL
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 15 Years
Maximum Age for this Clinical Trial: 85 Years
Clinical Trial Sponsor Information
Lead Sponsor: HaEmek Medical Center, Israel
Overall Clinical Trial Officials and Contacts
doron perez Principal Investigator Urology department: Haemek Medical Center
Overall Contact: DORON PEREZ, M.D. +972-4-6495115 perez_do@clalit.org.il
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00489723
Study ID Number: 0056-07-EMC
ClinicalTrials.gov Identifier: NCT00489723
Health Authority: Israel: Ethics Commission
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
